Dr. Giovanni Melillo obtained a Medical Doctor degree and a specialty in Medical Oncology from the University of Naples Medical School, Italy. Between 1999 and 2011 Dr. Melillo held the position of Senior Investigator with the Developmental Therapeutics Program of the National Cancer Institute at Frederick where he contributed to the implementation of a translational program for the discovery and development of small molecule inhibitors of Hypoxia Inducible Factor 1 and was involved in the design and implementation of phase I clinical trials of molecularly targeted agents in cancer patients. From 2011 until 2013 Dr. Melillo was Medical Director, Exploratory Clinical and Translational Research at Bristol-Myers Squibb in Princeton, NJ. Dr. Melillo is currently Senior Medical Director, Immuno-Oncology, Global Medicines Development with AstraZeneca in Gaithersburg, MD, where he is involved in developing novel immunotherapy agents for cancer. Dr. Melillo has served as Associate Editor of Cancer Research (2004-2012) and currently serves as AE of Journal of Molecular Medicine and is on the Editorial Board of Molecular Cancer Therapeutics, Cell Cycle, Molecular Cancer, and Cell Death and Disease.